941 studies (2 from unattributed sources) on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Polaris Peptides | 26 | 99.51% | View COA → |
| Qingdao Sigma Chemical | 23 | 99.51% | View COA → |
| Peptide Sciences | 21 | 99.71% | View COA → |
| Nexaph | 18 | 98.41% | View COA → |
| Simple Peptide | 16 | 99.86% | View COA → |
| Peptide Crafters | 16 | 99.8% | View COA → |
| (unknown) | 16 | 99.57% | View COA → |
| Aminos Research | 15 | 99.73% | View COA → |
Recent certificates: #63635 (99.885%) · #62991 (99.9%) · #42777 (99.91%) · #22090 (99.8%) · #22091 (99.7%) · #14540 (99.9%)
Manufacturers with published third-party certificates of analysis for Semaglutide. Open a vendor to see every batch we've verified.
This study introduces a promising alternative for **semaglutide administration**, potentially improving patient adherence by offering a non-injectable, sublingual option that outperforms existing oral tablets. For cli…
This review underscores the critical need for aesthetic surgeons to adapt their practices when managing patients on **GLP-1 RAs**. **Individualized perioperative planning, in coordination with anesthesiology and insti…
Oral semaglutide and empagliflozin's comparative efficacy and safety are being investigated in a global trial for Type 2 Diabetes Mellitus.
If **KAI-9531** demonstrates superior efficacy to semaglutide, it could represent a significant advancement in **obesity** pharmacotherapy, offering a potentially more effective option for weight management. **A new, …
A new study is recruiting patients to investigate how Semaglutide affects visceral adipose tissue and liver function in chronic kidney disease.
A real-world, non-interventional study will assess oral **Semaglutide** (Rybelsus®) effectiveness in lowering blood sugar in Swiss **Type 2 Diabetes** patients over 8-10 months.
If **Bofanglutide (GZR18)** demonstrates superior or comparable efficacy with a favorable safety profile, it could offer a valuable new option for individuals managing **overweight** or **obesity**, particularly those…
If successful, this trial could establish **semaglutide** as a novel therapeutic option for **Alcohol Use Disorder (AUD)**, addressing a significant unmet medical need. Current AUD treatments have limited efficacy for…
This real-world evidence significantly expands the understanding of **semaglutide 2.4 mg's** cardiovascular benefits, suggesting its utility for **primary prevention** in overweight/obese individuals at high risk for …
This case report significantly expands the known safety profile of **semaglutide**, highlighting a rare but serious potential complication: **spontaneous pneumomediastinum**. For peptide users and biohackers, this und…
This research identifies a novel mechanism by which `GLP-1R` activation, specifically with semaglutide, could offer a therapeutic avenue for **alcohol withdrawal-induced anxiety**. Given the high rates of relapse driv…
This real-world evidence strongly reinforces **semaglutide's superior effectiveness over dulaglutide for improving glycemic control and promoting weight loss in a broad Type 2 Diabetes population**. The finding that b…
Semaglutide significantly cut `HbA1c` by **0.71%**, weight by **4.77 kg**, and `SBP` by **3.56 mmHg** in UAE adults with **Type 2 Diabetes** over 12 months.
This review provides a critical roadmap for developing more effective and convenient oral **semaglutide** formulations, potentially expanding access and improving adherence for patients with **type 2 diabetes** and **…
This trial's approach to guiding cardioprotective therapy via a **`proteomic risk model`** could revolutionize how **Type 2 Diabetes (T2D)** patients receive crucial **CVD** prevention. If successful, such a model cou…
While the abstract does not present the findings of this specific study, the *intent* to generate real-world comparative effectiveness data for **semaglutide** and **dulaglutide** is highly significant. **Robust real-…
This case underscores a previously unreported but serious complication of GLP-1 RA therapy: transmural esophageal rupture, likely precipitated by drug-induced gastroparesis and forceful emesis. **Abrupt reinitiation o…
For individuals using **oral semaglutide** for obesity, **strict adherence to the specific administration protocol is paramount for achieving therapeutic efficacy**. This guidance underscores that skipping the `30-min…
The landscape for **MASH** treatment is undergoing a transformative shift, offering renewed hope for patients and clinicians. The accelerated approvals of **resmetirom** and **semaglutide** mean that effective, target…
This innovative method significantly **reduces the cost and complexity of generating radiolabeled peptides**, a critical bottleneck in peptide drug discovery and development. For researchers and biohackers working wit…
**Implementing a standardized 4-week semaglutide discontinuation protocol before aesthetic abdominoplasty is crucial for patient safety and improved surgical outcomes.** This finding provides clear, actionable guidanc…
Pharmacovigilance data links **GLP-1 receptor agonists**, particularly **semaglutide**, to gastric motility disorders, with semaglutide showing an ROR of **80.27** for impaired gastric emptying.
Multiple systematic reviews and meta-analyses investigate the rate and risk of nonarteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide use for diabetes and weight loss.
Semaglutide's influence on the pharmacokinetics of single doses of atorvastatin and digoxin is being investigated in healthy subjects.
An exploratory study is evaluating the efficacy and safety of **CS0159** combined with **Semaglutide** in patients with **MASH**, obesity, and type 2 diabetes.
A Canadian retrospective study is evaluating real-world semaglutide use on cardio-kidney-metabolic outcomes in adults with **T2D** and obesity.
If successful, this study could significantly impact the management of **Type 2 Diabetes** by establishing a more effective and potentially safer combination therapy. **The practical takeaway for clinicians and patien…
If successful, this Phase 2 trial could validate **TriGlytza®** as a superior long-term treatment for **Type 2 diabetes**, moving beyond symptomatic relief to address root causes like **inflammation** and **insulin re…
**If the ASSET trial demonstrates positive results, Semaglutide could revolutionize acute ischemic stroke management**, offering a critical adjunctive neuroprotective therapy beyond current reperfusion strategies. Thi…
The findings from this pharmacokinetic study are foundational for the safe and effective clinical use of **enlicitide decanoate** and **semaglutide** in combination. As patients with metabolic syndrome often present w…
This trial design is pivotal for advancing **individualized medical weight loss treatment**. By identifying potential predictors of response to obesity medication, clinicians could eventually tailor therapies more eff…
This real-world comparison provides crucial evidence that **patients with Type 2 Diabetes Mellitus can expect similar improvements in glycemic control and weight reduction regardless of whether they choose oral or sub…
This real-world data reinforces the dose-dependent efficacy of semaglutide in achieving significant glycemic control and reducing insulin requirements in **Type 2 Diabetes Mellitus** patients. **Clinicians can confide…
This meta-analysis reinforces the substantial efficacy of **GLP-1RA and incretin-based therapies for weight loss**, particularly when integrated with lifestyle interventions. For individuals managing overweight or obe…
**This consensus provides a critical roadmap for improving early detection and management of steatotic liver disease (SLD)**. For clinicians, it underscores the urgent need to integrate non-invasive fibrosis assessmen…
This research highlights a critical gap in public health policy across Europe, indicating that current frameworks are ill-equipped to manage the growing burden of **MASLD/MASH**. For clinicians and policymakers, the p…
This study highlights a novel therapeutic strategy for **pulmonary arterial hypertension** by targeting **ZIP12** and intracellular zinc. For biohackers and clinicians, **APL-9796** represents a potential new class of…
**Semaglutide** weight loss videos on YouTube often lack reliability. A study of **100** top videos found user-generated content low quality, academic sources higher.
**Understanding the real-world psychiatric safety profile and administration hurdles of GLP-1 RAs is crucial for clinicians and patients.** This analysis provides important insights beyond controlled clinical trials, …
The observed improvement in refractory **Restless Legs Syndrome** symptoms in a **Parkinson's Disease** patient treated with **Semaglutide** suggests a potential new therapeutic avenue for a challenging comorbidity. F…
This meta-analysis solidifies semaglutide's role as a potent therapeutic agent for **metabolic dysfunction-associated steatohepatitis (MASH)**, particularly in achieving histological resolution and reducing hepatic fa…
This real-world observational study is critical for understanding how **semaglutide** performs in a diverse clinical setting outside of highly controlled randomized trials, specifically within the Argentine population…
This Phase II trial is crucial for determining if **BGM0504** could offer a new, effective treatment option for **Type 2 Diabetes**, particularly for Chinese patients. If successful, it could provide an alternative or…
A randomized clinical trial will compare the pharmacokinetics of two semaglutide formulations delivered via different pen-injectors in individuals with overweight or obesity.
**Semaglutide** could represent a significant paradigm shift for managing newly diagnosed **Type 1 Diabetes**, moving beyond insulin replacement to potentially preserve endogenous insulin production. For clinicians, t…
This comprehensive meta-analysis provides strong reassurance that **oral semaglutide's real-world effectiveness and safety are consistent with its performance in controlled clinical trials**, validating its widespread…
This analysis provides critical pharmacoeconomic evidence for **clinical decision-making and health policy formulation in China**, particularly regarding the inclusion and reimbursement of `GLP-1R` agonists. The findi…
This commentary is crucial for shaping the future of **MASH** drug development and regulatory pathways. **Adopting longer duration and composite NIT endpoints could accelerate the approval of new therapies** by making…
A comprehensive meta-analysis of real-world evidence confirms oral semaglutide's efficacy and safety in managing **type 2 diabetes** and **obesity**.
Optimizing oral peptide delivery is critical for patient adherence and broader therapeutic access. This study's investigation into **semaglutide** Formulation III, particularly its focus on water volume and meal timin…
Free, no account — handy when you're working with Semaglutide.